- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07949890
Titrated Norepinephrine for Prophylaxis Against Intraoperative Hypotension in Emergency Surgery
Titrated Norepinephrine for Prophylaxis Against Intraoperative Hypotension in Emergency Surgery: a Randomized Controlled Trial
A titrated approach, initiating norepinephrine infusion only when non invasive mean arterial (MAP) falls below 75 mmHg, may provide more balanced hemodynamic control and reduce the risk of hypertension.
To the best of our knowledge, no studies have specifically evaluated prophylactic vasopressor use in patients undergoing emergency surgery for septic source control. In this study, we investigate the efficacy of titrated norepinephrine infusion as a prophylactic strategy against intraoperative hypotension in emergency surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maha M Mostafa, MD
- Phone Number: +2 01000365115
- Email: maha.mostafa@cu.edu.eg
Study Contact Backup
- Name: maha m mostafa, md
- Email: maha.mostafa11@gmail.com
Study Locations
-
-
-
Cairo, Egypt, 11562
- Kasr Alainy Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients (>18 years), ASA I-III undergoing emergency surgery for elimination of septic focus
Exclusion Criteria:
- Severe cardiac morbidities (impaired contractility with ejection fraction < 40%, heart block, arrhythmias, tight valvular lesions)
- Baseline MAP<75 mmHg
- Body mass index > 35 Kg/m2,
- Pregnant or lactating women,
- Allergy of any of the study drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: control
saline infusion |
500 mL of normal saline will be used without the addition of any drug. The managing anesthetist will withdraw the solution into a 50 mL syringe. When intraoperative mean arterial pressure (MAP) decreases to less than MAP 75 mmHg, saline will be infused at a rate of 0.75 mL/kg/h |
|
Active Comparator: prophylactic group
norepinephrine infusion |
4000 mcg of norepinephrine will be diluted in 500 mL of normal saline to yield a final concentration of 8 mcg/mL. The managing anesthetist will withdraw the solution into a 50 mL syringe. When intraoperative mean arterial pressure (MAP) decreases to less than MAP 75 mmHg, the prepared norepinephrine will be infused at a rate of 0.75 mL/kg/h |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
incidence of intraoperative hypotension
Time Frame: immediately after induction of anesthesia until extubation
|
MAP <65 mmHg or < 70 % of baseline |
immediately after induction of anesthesia until extubation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under a MAP of 65 mmHg
Time Frame: immediately after induction of anesthesia until extubation
|
immediately after induction of anesthesia until extubation
|
|
|
serum lactate
Time Frame: 30 minutes after extubation
|
30 minutes after extubation
|
|
|
acute kidney injury
Time Frame: 24 hours after surgery
|
24 hours after surgery
|
|
|
delirium
Time Frame: 24 hours after surgery
|
by Confusion Assessment Method (CAM) score |
24 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ahmed Hasanin, MD, Cairo University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Hypotension
- Organic Chemicals
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Amines
- Inorganic Chemicals
- Chlorine Compounds
- Catechols
- Phenols
- Benzene Derivatives
- Alcohols
- Amino Alcohols
- Ethanolamines
- Biogenic Monoamines
- Biogenic Amines
- Catecholamines
- Sodium Compounds
- Chlorides
- Hydrochloric Acid
- Norepinephrine
- Sodium Chloride
Other Study ID Numbers
- MD-298-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.